8-K: Henry Schein CEO Stanley Bergman to Retire End of 2025, Successor Search Initiated

Henry Schein, Inc. announced that long-serving Chief Executive Officer Stanley M. Bergman will retire at the end of 2025, remaining as Chairman, as the company initiates a formal search for his successor.

Summary

• Stanley M. Bergman will retire as Henry Schein, Inc.'s Chief Executive Officer (CEO) effective December 31, 2025, after 45 years with the company, including over 35 years as CEO.
• Mr. Bergman will continue to serve as Chairman of the Board of Directors following his retirement.
• Under Mr. Bergman's leadership, Henry Schein's revenue grew from $225 million in 1989 to almost $13 billion in 2024, representing an approximate compound annual growth rate (CAGR) of 17.5%.
• The company's market capitalization increased from $290 million at its 1995 IPO to a current value of almost $9 billion, excluding the 2019 spin-off of its animal health business.
• Henry Schein delivered a non-GAAP EPS CAGR of 12.4% from 1995 through Q4 2024.
• The Board is commencing a formal search process with a nationally recognized executive search firm to identify Mr. Bergman's successor, considering both internal and external candidates.
• The company has transformed from a small, U.S.-based dental mail order company into the largest global full-service dental distributor and a leading medical distributor.
• Key accomplishments include building the largest provider of global dental practice management software and digital services, and creating a fast-growing dental specialties business.
• Higher growth, higher margin businesses and corporate-brand products now contribute over 50% of total non-GAAP operating income under the BOLD+1 strategic plan.
• The company recently simplified its business into three operating divisions, each with strong leadership, as part of succession planning.

Sentiment

Score: 8

Explanation: The announcement of a long-serving CEO's retirement is handled very positively, emphasizing his significant achievements, the company's strong financial performance under his leadership, and a well-planned succession process. The continuity of his role as Chairman and the existing strong management team contribute to a positive outlook despite the leadership change.

Positives

• Strong historical growth under Stanley Bergman's leadership, with revenue CAGR of 17.5% from $225 million in 1989 to almost $13 billion in 2024.
• Significant increase in market capitalization from $290 million at its 1995 IPO to nearly $9 billion currently.
• Consistent profitability growth demonstrated by a non-GAAP EPS CAGR of 12.4% from 1995 to Q4 2024.
• Successful transformation into a global leader in dental and medical products and solutions, including becoming the largest global dental practice management software provider.
• Achievement of strategic goals under the BOLD+1 plan, with higher growth and margin businesses contributing over 50% of non-GAAP operating income.
• Established leadership in advancing public-private partnerships for access to care, disaster relief, and pandemic preparedness.
• A well-structured succession plan is in place, including a formal search process and the continuity of Mr. Bergman as Chairman.
• The company has developed next-generation leaders and simplified its business into three operating divisions with strong existing leadership.

Risks

• Dependence on third parties for the manufacture and supply of products, raw materials, or purchased components.
• Challenges in achieving strategic growth objectives.
• Risks associated with the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in January 2025.
• Ability to develop or acquire, maintain, and protect new products (particularly technology products) and services that achieve market acceptance with acceptable margins.
• Transitional challenges related to acquisitions, dispositions, and joint ventures, including failure to achieve anticipated synergies/benefits and significant demands on operational and human resources.
• Provisions in governing documents that may discourage third-party acquisitions.
• Adverse changes in supplier rebates or other purchasing incentives.
• Risks related to the sale of corporate brand products.
• Risks related to activist investors.
• Security risks associated with information systems and technology products/services, such as cyberattacks or data security breaches (including the October 2023 incident).
• Effects of a highly competitive and consolidating market, including competition from third-party online commerce sites.
• Changes in the healthcare industry.
• Risks from expansion of customer purchasing power and multi-tiered costing structures.
• Increases in shipping costs or other service issues with third-party shippers, and increases in fuel and energy costs.
• Changes in laws and policies governing manufacturing, development, and investment in territories and countries of operation.
• General global and domestic macro-economic and political conditions, including inflation, deflation, recession, unemployment, consumer confidence, sovereign debt levels, ongoing wars, fluctuations in energy pricing, and the value of the U.S. dollar.
• The threat or outbreak of war, terrorism, or public unrest (e.g., war in Ukraine, Israel-Gaza war, Middle East unrest).
• Changes to laws and policies governing foreign trade, tariffs, and sanctions, including new U.S. tariffs and potential retaliatory tariffs.
• Greater restrictions on imports and exports.
• Supply chain disruption.
• Geopolitical wars.
• Failure to comply with existing and future regulatory requirements, including those related to healthcare and the EU Medical Device Regulation.
• Failure to comply with laws and regulations relating to healthcare fraud, collection/storage/processing of sensitive personal information, or electronic health records/transmissions.
• Changes in tax legislation, tax rates, and availability of certain tax deductions.
• Risks related to product liability, intellectual property, and other claims.
• Risks associated with customs policies or legislative import restrictions.
• Risks associated with disease outbreaks, epidemics, pandemics (such as COVID-19), or similar widespread public health concerns and other natural or man-made disasters.
• Risks associated with global operations.
• Litigation risks, including new or unanticipated litigation developments.
• Dependence on senior management, employee hiring and retention, increases in labor costs or healthcare costs, and relationships with customers, suppliers, and manufacturers.
• Disruptions in financial markets.

Future Outlook

The company is well-positioned for the future, with a focus on developing the next generation of leaders and continuing to advance the BOLD+1 strategy. Management expects to work with KKR on value creation initiatives and a broad-based employee ownership program.

Management Comments

• "With the progress made advancing our BOLD+1 strategic plan and with strong management in place, it is the right time for me to retire at the end of the year." Stanley M. Bergman
• "I look forward to working with the Board to identify my successor and effect a smooth transition." Stanley M. Bergman
• "Henry Schein has been my professional home for 45 years and I will conclude this chapter of my life with enormous gratitude for the opportunity to serve as CEO and with great confidence in the Company’s future." Stanley M. Bergman
• "Under Stan’s leadership, Henry Schein has become the global leader in providing dental and medical products and solutions for health care providers in alternate care settings, and we recognize the significant impact he has had on the Company and the entire health care industry." Philip A. Laskawy, Lead Director
• "We owe a tremendous debt of gratitude to Stan for his steadfast devotion to Henry Schein and for bringing his unique blend of strategic vision, attention to detail, and entrepreneurship to the Company." Philip A. Laskawy, Lead Director
• "It has been my greatest privilege to lead Team Schein over the past 35-plus years. Guided by our purpose-driven mission, we have built an agile Company that is able to meet the changing needs of our customers, has created significant shareholder value, and is well positioned for the future." Stanley M. Bergman
• "I fully expect that Andrea Albertini, CEO of the Global Distribution Group who also has responsibility for the Global Technology Group, and Tom Popeck, CEO of the Health Care Specialties Group, together with the rest of the Company’s Executive Management Committee, will elevate Henry Schein to new heights by continuing to advance the BOLD+1 strategy and working with KKR on value creation initiatives and a broad-based employee ownership program." Stanley M. Bergman
• "I am especially pleased to have worked with tens of thousands of incredibly committed and talented Team Schein Members who helped reimagine and reinvent Henry Schein’s role, from one of product delivery and logistics to one whose mission today is to help our over 1 million health care professionals operate better and more efficient practices so our customers can concentrate on delivering the best quality patient care." Stanley M. Bergman (from his letter)
• "With the team continuing to balance the Company’s five constituents that make up the Henry Schein Mosaic of Success (suppliers, customers, investors, employees, and society at large) and maintaining the values of Team Schein, I believe that Henry Schein’s best years are yet to come." Stanley M. Bergman

Industry Context

The announcement highlights Henry Schein's transformation into a global leader in dental and medical products and solutions, serving office-based practitioners and alternate care sites. This reflects a broader trend in healthcare towards integrated solutions, digital services, and specialized care, moving beyond traditional product distribution. The company's focus on public-private partnerships also aligns with increasing industry emphasis on access to care and public health infrastructure.

Comparison to Industry Standards

• Henry Schein has grown from a small, U.S.-based primarily dental mail order company to the largest global full-service dental distributor and a leading medical distributor to alternate care sites.
• The company built what is now the largest provider of global dental practice management software and digital services.
• It created a fast-growing dental specialties business, including the 2nd-largest provider of endodontic products and 3rd-largest provider of dental implant and bone regeneration products.
• The company's revenue growth from $225 million in 1989 to almost $13 billion in 2024, representing an approximate compound annual growth rate of 17.5%, demonstrates exceptional long-term performance compared to many mature distribution and healthcare services companies.
• The market capitalization growth from $290 million at its 1995 IPO to almost $9 billion (excluding the 2019 animal health spin-off) indicates significant shareholder value creation.
• The non-GAAP EPS CAGR of 12.4% over the same period (1995-Q4 2024) suggests strong profitability growth.
• The achievement of over 50% of total non-GAAP operating income from higher growth, higher margin businesses and corporate-brand products under the BOLD+1 strategic plan indicates successful portfolio optimization, which is a key strategic goal for many diversified healthcare companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for continued value creation given strong historical performance and planned succession. The continuity of Mr. Bergman as Chairman and the structured search process aim to minimize disruption.
• Employees (Team Schein Members): Mr. Bergman thanked them for their contributions, and the company is focusing on developing the next generation of leaders. A broad-based employee ownership program is mentioned in conjunction with KKR.
• Customers: The company's mission is to help over 1 million healthcare professionals operate better and more efficient practices, ensuring continued quality patient care.
• Suppliers: Part of the 'Henry Schein Mosaic of Success,' indicating continued importance of these relationships.
• Society at large: Company's global leadership in advancing public-private partnerships for access to care, disaster relief, and pandemic preparedness.

Next Steps

• Formal search process for a new CEO by the Board in conjunction with a nationally recognized executive search firm.
• Identification of a successor for Stanley M. Bergman.
• Smooth transition of CEO responsibilities by December 31, 2025.
• Continued advancement of the BOLD+1 strategy by the Executive Management Committee.
• Working with KKR on value creation initiatives and a broad-based employee ownership program.

Key Dates

Recommendation

Keywords

Henry Schein, HSIC, CEO retirement, Stanley Bergman, healthcare solutions, dental, medical, distribution, corporate governance, succession planning, financial performance, BOLD+1 strategy, market capitalization, revenue growth, EPS